ascendis pharma glp-1 receptor agonists weight management diabetes treatments agonist medications Emerging Trends in the Development of GLP-1 Receptor Clinical Management of Weight Regain
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 41.Drucker DJ
Supplementary Information Additional file 1: Table S1
The study found that weight regain was relatively minimal, whether subjects lost weight from injectable semaglutide (Wegovy) or tirzepatide
[DOI] [PMC free article] [PubMed] [Google Scholar] 3.Rosol T.J
Additionally, follow-up at 31 weeks showed no difference in eGFR between the placebo and oral-semaglutide groups compared with baseline eGFR measurements, suggesting that treatment had no adverse effects on kidney function
